The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net income | 191,461 | 55,344 |
| Depreciation and amortization | 55,663 | 40,809 |
| Amortization and write-off of deferred financing fees | 3,148 | 3,115 |
| Stock-based compensation | 54,069 | 115,544 |
| Loss on investment in partnership | -773 | -4,565 |
| Gain on insurance subsidiary deposits and investments | 4,896 | 1,258 |
| Deferred taxes | -17,733 | -44,484 |
| Noncash lease expense | 48,454 | 34,647 |
| Other noncash operating activities | 573 | 843 |
| Accounts receivable, net | -13,647 | 93,968 |
| Other receivables | -781 | 22,487 |
| Prepaid expenses and other current assets | 69,523 | 17,210 |
| Other assets | 2,660 | 13,338 |
| Escrow funds | -6,718 | 9,473 |
| Operating lease liabilities | -1,196 | -20,784 |
| Accounts payable | 14,856 | 33,398 |
| Accrued payroll and benefits | 40,992 | 52,041 |
| Accrued self-insurance liabilities | 80,610 | 67,242 |
| Refund liability | 35,334 | 145,795 |
| Other accrued expenses | 13,227 | 73,210 |
| Other liabilities | -60,074 | -36,210 |
| Net cash provided by operating activities | 404,224 | 367,341 |
| Investment in partnerships | 0 | 32,891 |
| Non-operating distributions from investment in partnership | 5,593 | 3,521 |
| Purchase of available-for-sale securities | 21,212 | 90,874 |
| Sale of available-for-sale securities | 0 | 25,874 |
| Acquisition of facilities | 143,751 | 283,344 |
| Purchase of property and equipment | 105,405 | 66,465 |
| Proceeds from the sale of assets | 750 | 1,500 |
| Net cash used in investing activities | -264,025 | -442,679 |
| Borrowing on lines of credit, net of deferred financing fees | 0 | 676,000 |
| Payments on lines of credit | 42,000 | 1,054,000 |
| Borrowings of long-term debt, net of deferred financing fees | 0 | 72,305 |
| Payments on long-term debt | 18,218 | 19,455 |
| Noncontrolling interest distribution | 377 | - |
| Contributions from noncontrolling interest | 0 | 502 |
| Dividends on common stock | 0 | 33,721 |
| Proceeds from initial public offering, net of issuance costs | 0 | 414,157 |
| Proceeds from common stock offering, net of issuance costs | 0 | 95,285 |
| Taxes paid related to net share settlement of equity awards | 8,395 | 33,597 |
| Net cash (used in)/provided by financing activities | -68,990 | 117,476 |
| Net change in cash | 71,209 | 42,138 |
| Cash, cash equivalents, and restricted cash - beginning of period | 160,842 | 118,704 |
| Cash, cash equivalents, and restricted cash - end of period | 232,051 | 160,842 |
PACS Group, Inc. (PACS)
PACS Group, Inc. (PACS)